from Fly on the Wall 11/07 MACK pancreatic ca trial, "This change is based on a blinded assessment of overall survival events across the entire trial, which are occurring later than forecasted. As previously disclosed, Merrimack met its enrollment target for the trial in August 2013."
Interesting, Jeff. MACK was on my watchlist for a while but they dropped off at some point and I don't know why. It was before the misinterpretation of their ovarian CA trial - which actually showed impressive results in targeted population...So thank you very much. I see their sp has dropped to good entry point, love this extension of pancreatic trial, love that they can now create biomarker specific ovarian ca ph3 - should be impressive results.
Thank you, thank you. Don't know how I almost forgot about them! I'll put some profits from CYTR run last month, which I made from CTIX taking-it-off-the-table-profit, and make some MACK profit. Keeping it in motion!